|
|
|
|
|
Fentanyl_Citrate: profile and news
Cephalon Reports Outstanding Financial Results for 2005 Feb 14, 2006 Cephalon Reports Outstanding Financial Results for 2005 Feb 14, 2006 Barr Announces Agreements With Cephalon, Inc. Regarding Settlement ... Feb 1, 2006 Cephalon, Inc. Announces Agreements With Barr Laboratories, Inc. ... Feb 1, 2006 Cephalon, Inc. Provides Update on Regulatory Status of NUVIGIL(TM) Feb 1, 2006 Cephalon, Inc. Provides Update on Regulatory Status of NUVIGIL(TM) Feb 1, 2006 Barr Announces Agreements With Cephalon, Inc. Regarding Settlement ... Feb 1, 2006 Cephalon, Inc. Provides Update on Regulatory Status of NUVIGIL Feb 2, 2006 Studies Confirm Effectiveness Of Fentanyl Lozenges For ' ... Jan 25, 2006 Cephalon, Inc. Announces Agreements With Barr Laboratories, Inc. ... Feb 1, 2006 2d Plymouth paramedic fired Jan 28, 2006 Horst Witzel, Dr.-Ing., to Retire From Cephalon Board of Directors Jan 31, 2006 Cephalon, Inc. Provides Update on Regulatory Status of SPARLON(TM) Jan 25, 2006 Horst Witzel, Dr.-Ing., to Retire From Cephalon Board of Directors Jan 31, 2006 Scientific Advances on Three Lead Cephalon Oncology Compounds to ... Dec 8, 2005 Source: Cephalon, Inc.; Zeneus Holdings Limited Dec 5, 2005 FDA Approvals: Nevanac, Sugar-Free Actiq, Quinine Sulfate Sep 15, 2005 Cephalon Receives FDA Approval to Market Sugar-Free Formulation of ... Sep 12, 2005 FDA Extends PDUFA Date for VIVITREX(R) to December 30, 2005 ... Sep 20, 2005 Cephalon Files New Drug Application for OraVescent(R) Fentanyl for ... Sep 6, 2005 Cephalon, Inc. Announces Agreement With McNeil Consumer & ... Sep 1, 2005 Cephalon Receives Approval to Market Modafinil for Shift Work ... Aug 30, 2005 Cephalon Board Member Gail Wilensky Appointed to World Health ... Aug 25, 2005 Cephalon Board Member Gail Wilensky Appointed to World Health ... Aug 25, 2005 Cephalon Receives Approval to Market Modafinil for Shift Work ... Aug 30, 2005 New England Journal of Medicine Publishes First Clinical Study of ... Aug 4, 2005 New England Journal of Medicine Publishes First Clinical Study of ... Aug 3, 2005 Cephalon Reports Continued Strong Growth in Second Quarter Aug 2, 2005 Cephalon Reports Continued Strong Growth in Second Quarter Aug 2, 2005 Cephalon, Inc. Completes Acquisition of TRISENOX From Cell ... Jul 19, 2005 Cephalon, Inc. Completes Acquisition of TRISENOX(R) From Cell ... Jul 19, 2005 Cephalon, Inc. Accepts Notes Tendered Pursuant to Offer for 2-1/2 ... Jul 12, 2005 Cephalon Announces Exercise of $120 Million Over-allotment Option ... Jul 1, 2005 Cephalon Announces Exercise of $120 Million Over-allotment Option ... Jul 1, 2005 Cephalon, Inc. Announces Acquisition of TRISENOX(R) from Cell Jun 13, 2005 Cephalon and Alkermes Announce Agreement for the Commercialization ... Jun 24, 2005 Cephalon and Alkermes Announce Agreement for the Commercialization ... Jun 24, 2005 Cephalon, Inc. Announces Acquisition of TRISENOX(R) from Cell ... Jun 13, 2005 Other information Indication For the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy. Pharmacology Fentanyl is an opioid analgesic. Fentanyl interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, Fentanyl exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Fentanyl may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Fentanyl depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. Mechanism Of Action Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Fentanyl's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. Drug Category Anesthetics; Narcotics; Adjuvants; Analgesics; Opiate Agonists; ATC:N01AH01; ATC:N02AB03 Brand Names/Synonyms Actiq; CHEMBANK1683; Dea No. 9801; Duragesic; Duragesic-100; Durogesic; F5886; Fentanest; Fentanil; Fentanil [Dcit]; Fentanila; Fentanila [Inn-Spanish]; Fentanyl; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Fentanylum; Fentanylum [Inn-Latin]; HSDB 3329; Pentanyl; Phentanyl; R 4263; Sentonil; Sublimaze; Sublimaze Preservative Free Dosage Forms DISC (SUSTAINED-RELEASE); LIQUID; SOLUTION Absorption Not Available Interactions Interactions for Fentanyl: Agents Affecting Cytochrome P450 3A4 Isoenzyme System Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when DURAGESIC® is given concurrently with agents that affect CYP3A4 activity. Coadminstration with agents that induce 3A4 activity may reduce the efficacy of DURAGESIC®. The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations. The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression. In this situation, special patient care and observation are appropriate. Central Nervous System Depressants The concomitant use of DURAGESIC® (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death. When such combined therapy is contemplated, the dose of one or both agents should be significantly reduced. MAO Inhibitors DURAGESIC® is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics. -->Chemical IUPAC Name N-(1-phenethyl-4-piperidyl)-N-phenyl-propanamide Chemical Formula C22H28N2O Half Life 7 (range 3-12) hours Drug Type Approved Drug # Accession No APRD00347 CAS Registry Number 437-38-7 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |